Overview
Ceylon Hospitals operates the Durdans hospital, diagnostics and laboratory network, and related medical education businesses. The central change is that revenue and net profit continued to rise in the latest quarter, but the hospital group converted less of its revenue into operating profit than a year earlier.
Price performance
At LKR 57.00 on 20 October 2026, CHL had fallen 8.1% over three months against a 5.8% ASPI decline, while its 20.6% one-year return remained well ahead of the index’s 9.9% fall. The share sits 22.1% of the way up its adjusted 52-week range, after a 1:4 split on 5 March 2026 mechanically changed the screen price and share count but not the size of the company.
Recent volatility and volume are below this share’s own yearly norms. The three-year record contains two falls of 15% or more, with the deepest 40% and not yet recovered. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day, 405% of it, so a position of that size is a large part of normal trading activity.
Valuation
The market-wide assessment starts in the moderately undervalued band, scoring 74 of 100 on price against filed book value, earnings and dividends. At 10.0 rupees paid for every rupee of trailing profit, the P/E is close to the healthcare median of 10.58 times; the 0.8 times P/B means the shares trade below the LKR 71.56 per-share book value and below the sector median of 1.54 times. The 8.1% trailing return on equity is the link between those earnings and book value.
Against its own record, P/B is “more expensive than 80% of days since January 2019” and P/E is “more expensive than 65% of days since January 2019”. That contrast with sector-relative discounts means the present price is cheaper than comparable healthcare shares on book value, but not cheap against CHL’s own trading record. A buyer at this price is relying on a latest quarter that supplied 29.7% of trailing EPS; at the prior-year quarter’s margin, the P/E would be 9.9 times rather than 10.0 times.
The 1.9% dividend yield is below the sector median of 2.7%. The payout has risen from LKR 0.5 per share in FY2024 to LKR 1.0 in FY2025 and LKR 1.1 in FY2026, while dividend cover was 5.16 times, leaving most earnings within the business.
News and sentiment
Direct company coverage is thin, with one material article in the past 90 days and neutral reported tone. An article dated 19 October reported that Durdans exited Digital Health, the Doc990 operator; no terms attributable to Ceylon Hospitals were disclosed, so its earnings effect cannot be sized.
The LKR 1.10 interim dividend went ex-dividend on 1 June 2026 and was paid on 18 June. A buyer today does not receive that dividend. The 1:4 subdivision took effect on 5 March 2026 and changed every per-share figure mechanically, without changing the group’s underlying assets or earnings.
Financials
June-quarter revenue rose 8.5% to LKR 3.0 billion, but operating profit fell 6.6% to LKR 427 million. Net profit nonetheless rose 4.7% to LKR 323 million, meaning the profit increase was smaller than sales growth and core operating performance softened.
Gross margin narrowed from 59.2% to 56.9%, operating margin from 16.6% to 14.3%, and net margin from 11.2% to 10.8%. The June gross margin was among the weakest of seven comparable June quarters, while operating and net margins ranked in the middle of that record. LKR 104 million was absorbed below operating profit by finance costs, tax and other items, which limited the amount of operating earnings reaching net profit.
Total equity rose from LKR 12.1 billion a year earlier to LKR 12.9 billion. Shares in issue are 167.6 million, compared with about 42.0 million before the March split; the fourfold increase is mechanical, so historic EPS and book value per share cannot be read as an underlying deterioration. The twelve months to June 2026 generated LKR 11.2 billion of revenue and an 8.1% return on equity. Minority shareholders received 9.6% of the latest audited year’s profit, so group net profit is not entirely attributable to the ordinary shares being valued.
Risks
The leading business risk is margin pressure: the latest quarter produced more revenue but less operating profit, and gross margin ranked near the bottom of its comparable June record. Healthcare-sector context also points to household pressure, with essentials including healthcare accounting for 58% of spending in the cited survey; this is an industry backdrop rather than evidence of a measured effect on CHL.
Balance-sheet risk is moderate rather than acute. Debt was LKR 1.3 billion at the latest audited year-end, equal to 11.2% of owners’ equity, and operating profit covered the interest bill 8.1 times. The current ratio was 1.47 times, meaning it had LKR 1.47 of short-term assets, including receivables and supplies, for each LKR 1 of bills due within a year. Operating cash flow was 1.07 times operating profit, so audited operating earnings were converted into cash, while free cash flow was LKR 920 million.
The voting line is also illiquid, and the share’s record includes a still-unrecovered 40% drawdown. This makes trading access and exit capacity a practical risk independent of the group’s operating results.
Outlook
As at 20 October 2026, the next specific catalyst is the September 2026 interim filing, expected between 6 and 14 November. It will show whether June’s lower operating margin was a one-quarter setback or whether revenue growth is continuing to outpace profit growth.
The available data cannot quantify the effect of the reported Doc990 exit. The healthcare backdrop combines higher public health allocations with household-budget pressure, but neither development establishes a direct impact on Ceylon Hospitals’ revenue or earnings.